Use of bedaquiline in the treatment of a patient with extensively drug-resistant pulmonary tuberculosis
More details
Hide details
Respiratory Infections Unit, Pulmonary Department, Aristotle University of Thessaloniki, G. Papanikolaou Hospital, Exohi, Thessaloniki, Greece
TB Department, Sotiria Chest Diseases Hospital, Athens, Greece
National Reference Center for Mycobacteria, Sotiria Chest Diseases Hospital, Athens, Greece
Publication date: 2021-06-17
Corresponding author
Katerina Manika   

“G. Papanikolaou” Hospital, 57010 Exohi, Thessaloniki
Pneumon 2016;29(1):53-57
A 27-year-old man from the former Soviet Union with unremarkable medical history was diagnosed with pulmonary tuberculosis and was initially treated with the standard antituberculosis regimen (R, H, E, Z). Based on the sputum molecular analysis for M. tuberculosis the diagnosis of multidrug-resistant tuberculosis (MDR-TB) at first and later of extensively drug-resistant tuberculosis (XDR-TB) was made. The patient received a complex antituberculosis regimen, which included ethionamide, pyrazinamide, capreomycin, imipenem /cilastatin, linezolid and an increased dose of moxifloxacin at 600 mg. Due to the limited number of drugs that were active in vitro in the above regimen, bedaquiline was added for six months, and moxifloxacin was discontinued. The patient showed significant clinical and radiological improvement, increase in body weight, reduction of his cavities’ size and culture conversion, without severe side effects. After one year of hospitalization, the patient was discharged on a regimen of capreomycin, linezolid, clofazimine, pyrazinamide, ethionamide and moxifloxacin and is still followed up in the outpatient clinic for tuberculosis of AUTH’s Pulmonary Department on a weekly basis. Treatment time is estimated at 18 months after culture conversion.
World Health Organization (WHO). The use of bedaquiline in the treatment of multidrug-resistant tuberculosis Interim policy guidance. Global tuberculosis report 2013. WHO, Geneva, Switzerland.
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis 2015;6:170-84.
Kurbatova EV, Dalton T, Ershova J, et al. Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries. Emerg Infect Dis 2015;21:977-83.
Worley MV, Estrada SJ. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy 2014;34:1187-97.
Nagabushan H, Roopadevi HS. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis. J Postgrad Med 2014;60:300-2.
Leibert E, Danckers M, Rom WN. New drugs to treat multidrugresistant tuberculosis: the case for bedaquiline. Ther Clin Risk Manag 2014; 10:597-602.
Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev 2013;9:200-10.
Esposito S, Bianchini S, Blasi F. Bedaquiline and delamanid in tuberculosis. Expert Opin Pharmacother 2015; 21:1-12.
WHO/HTM/TB/2014.23 Interim policy guidance on the use of delamanid in the treatment of MDR-TB.
Hards K, Robson JR, Berney M, et al. Bactericidal mode of action of bedaquiline. J Antimicrob Chemother 2015; 70:2028-37.
Fox GJ, Menzies D. A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis. Infect Dis Ther 2013;2:123-44.
Diacon AH, Lounis N, Dannemann B. Multidrug-resistant tuberculosis and bedaquiline. N Engl J Med 2014; 371:2436.
Wolfson LJ, Walker A, Hettle R, et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One 2015; 20;10:e0120763.
Philley JV, Wallace RJ Jr, Benwill JL, et al. Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease. Chest 2015;148:499-506.
Köser CU, Javid B, Liddell K, et al. Drug-resistance mechanisms and tuberculosis drugs. Lancet. 2015;385:305-7.
Wang H, Zhang X, Bai Y, et al. Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis. J Clin Bioinforma 2015;5:5.
Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60:188-94.
Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother 2015;70:1106-14.
Grossman TH, Shoen CM, Jones SM, Jones PL, Cynamon MH, Locher CP. The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. Antimicrob Agents Chemother 2015;59:1534-41.
Meintjes G. Management of drug-resistant TB in patients with HIV co-infection. J Int AIDS Soc 2014;17(4 Suppl 3):19508.
Gupta S, Tyagi S, Bishai WR. Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Antimicrob Agents Chemother 2015;59:673-6.
Bélard S, Heuvelings CC, Janssen S, Grobusch MP. Bedaquiline for the treatment of drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015;13:535-53.
Sotgiu G, Centis R, D’ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med 2015;5:a017822.
van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother. 2014;69:2310-8.
McLeay SC, Vis P, van Heeswijk RP, Green B. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother 2014;58:5315-24.
Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC. Novel drugs against tuberculosis: a clinician’s perspective. Eur Respir J 2015;45:1119-31.
Catho G, Couraud S, Grard S, et al. Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting. Clin Microbiol Infect 2015; 21:472.e7-472.
Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015;191:943-53.
Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis (Edinb) 2014;94:357-62.
Conradie F, Meintjes G, Hughes J, et al. Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. S Afr Med J 2014;104:164-6.
Gold B, Roberts J, Ling Y, et al. Rapid, semi-quantitative assay to discriminate among compounds with activity against replicating or non-replicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015;59:6521-38.
Srikrishna G, Gupta S, Dooley KE, Bishai WR. Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment. Future Microbiol 2015; 10:1257-60.
Schaberg T, Otto-Knapp R, Bauer T. New Drugs for the Treatment of Multidrug-resistant Tuberculosis (MDR-TB). Pneumologie 2015;69:282-6.
Mingote LR, Namutamba D, Seaworth B, Lee C, Frick MW. Informed use of bedaquiline for tuberculosis--Authors’ reply. Lancet. 2015;385:1725.
Lessem EM, Bernardo J, Reed C, Wegener DH. Informed use of bedaquiline for tuberculosis. Lancet. 2015;385:1724.
Keller PM, Hömke R, Ritter C, Valsesia G, Bloemberg GV, Böttger EC. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrob Agents Chemother 2015;59:4352-5.
Journals System - logo
Scroll to top